Transcutaneous supraorbital neurostimulation for acute treatment of chronic migraine: open-label preliminary data

2018 ◽  
Vol 39 (S1) ◽  
pp. 163-164 ◽  
Author(s):  
Paola Di Fiore ◽  
Alberto Galli ◽  
Giacomo D’Arrigo ◽  
Gennaro Bussone ◽  
Henri Didier ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Preliminary Data ◽  
Acute Treatment ◽  
Open Label

scholarly journals Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study

PAIN Reports ◽  
2021 ◽  
Vol 6 (4) ◽  
pp. e966
Author(s):  
Brian Grosberg ◽  
Liron Rabany ◽  
Tamar Lin ◽  
Dagan Harris ◽  
Maya Vizel ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Acute Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy ◽  
Electrical Neuromodulation

scholarly journals Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study

2015 ◽  
Vol 16 (1) ◽  
Author(s):  
Piero Barbanti ◽  
Licia Grazzi ◽  
Gabriella Egeo ◽  
Anna Maria Padovan ◽  
Eric Liebler ◽  
...  
Keyword(s):  
Vagus Nerve ◽  
Chronic Migraine ◽  
Nerve Stimulation ◽  
High Frequency ◽  
Vagus Nerve Stimulation ◽  
Acute Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Non Invasive

scholarly journals Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study

2020 ◽  
Vol 9 (2) ◽  
pp. 531-543
Author(s):  
Hida Nierenburg ◽  
Julio R. Vieira ◽  
Nirit Lev ◽  
Tamar Lin ◽  
Dagan Harris ◽  
...  
Keyword(s):  
Pilot Study ◽  
Chronic Migraine ◽  
Acute Treatment ◽  
Open Label ◽  
Electrical Neuromodulation

scholarly journals Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Messoud Ashina ◽  
Joshua M. Cohen ◽  
Maja Galic ◽  
Verena Ramirez Campos ◽  
Steve Barash ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Medication Use ◽  
Episodic Migraine ◽  
Inadequate Response ◽  
Open Label ◽  
Double Blind ◽  
Moderate Severity ◽  
Preventive Medication ◽  
Open Label Extension ◽  
Acute Headache

Abstract Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) selectively targets the calcitonin gene-related peptide and has proven efficacy for the preventive treatment of migraine. In this study, we evaluated the long-term efficacy, safety, and tolerability of monthly and quarterly fremanezumab. Methods Episodic migraine and chronic migraine patients completing the 12-week double-blind period of the FOCUS trial entered the 12-week open-label extension and received 3 monthly doses of fremanezumab (225 mg). Changes from baseline in monthly migraine days, monthly headache days of at least moderate severity, days of acute headache medication use, days with photophobia/phonophobia, days with nausea or vomiting, disability scores, and proportion of patients achieving a ≥50% or  ≥75% reduction in monthly migraine days were evaluated. Results Of the 807 patients who completed the 12-week double-blind treatment period and entered the open-label extension, 772 patients completed the study. In the placebo, quarterly fremanezumab, and monthly fremanezumab dosing regimens, respectively, patients had fewer average monthly migraine days (mean [standard deviation] change from baseline: − 4.7 [5.4]; − 5.1 [4.7]; − 5.5 [5.0]), monthly headache days of at least moderate severity (− 4.5 [5.0]; − 4.8 [4.5]; − 5.2 [4.9]), days per month of acute headache medication use (− 4.3 [5.2]; − 4.9 [4.6]; − 4.8 [4.9]), days with photophobia/phonophobia (− 3.1 [5.3]; − 3.4 [5.3]; − 4.0 [5.2]), and days with nausea or vomiting (− 2.3 [4.6]; − 3.1 [4.5]; − 3.0 [4.4]). During the 12-week open-label extension, 38%, 45%, and 46% of patients, respectively, achieved a ≥50% reduction and 16%, 15%, and 20%, respectively, achieved a ≥75% reduction in monthly migraine days. Disability scores were substantially improved in all 3 treatment groups. There were low rates of adverse events leading to discontinuation (<1%). Conclusion Fremanezumab demonstrated sustained efficacy up to 6 months and was well tolerated in patients with episodic migraine or chronic migraine and documented inadequate response to multiple migraine preventive medication classes. Trial registration ClinicalTrials.gov NCT03308968 (FOCUS).

Long-Term, Open-Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents

2008 ◽  
Vol 50 (5) ◽  
pp. 795-807 ◽  
Author(s):  
Frank Berenson ◽  
Elza Vasconcellos ◽  
Ann Pakalnis ◽  
Lian Mao ◽  
David M. Biondi ◽  
...  
Keyword(s):  
Acute Treatment ◽  
Open Label ◽  
Safety Study
Sign in / Sign up

Export Citation Format

Share Document